Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study
Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsukuda S, Yokohama F, Sogo M, Nishibe T, Matsuo N, Hirohata S, Ito H, Doi M
International journal of cardiology · 72 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2016-11-09 · Int J Cardiol · vol. 228 · págs. 173–179
- Editorial
- Elsevier BV
- Citado
- 88 citas · más que el 98% de estudios similares · 9.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 44 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Eicosanoids and Hypertension Pharmacology
- Palabras clave
- Medicine, Internal medicine, Hazard ratio, Clinical endpoint, Acute coronary syndrome, Myocardial infarction, Statin, Eicosapentaenoic acid, Percutaneous coronary intervention, Conventional PCI, Randomized controlled trial, Cardiology, Pitavastatin, Adverse effect, Confidence interval, Polyunsaturated fatty acid
- MeSH
- humans, quinolines, eicosapentaenoic acid, hydroxymethylglutaryl-coa reductase inhibitors, treatment outcome, drug therapy, combination, drug administration schedule, prospective studies, aged, middle aged, female, male, acute coronary syndrome, percutaneous coronary intervention
13 autores
- Kazumasa Nosaka🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Toru Miyoshi🇯🇵 · autor de correspondenciaOkayama University
- Mutsumi Iwamoto🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Masahito Kajiya🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Keisuke Okawa🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Saori Tsukuda🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Fumi Yokohama🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Masahiro Sogo🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Tomoyuki Nishibe🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Naoaki Matsuo🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
- Satoshi Hirohata🇯🇵 · autor de correspondenciaOkayama University
- Hiroshi Ito🇯🇵 · autor de correspondenciaOkayama University
- Masayuki Doi🇯🇵 · autor de correspondenciaKagawa Prefectural Central Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Early initiation of EPA treatment in combination with a statin within 24h after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) reduces inflammation and ventricular arrhythmia compared with statin monotherapy; however, the impact of early initiation of EPA treatment on cardiovascular events is unclear. We determined whether early eicosapentaenoic acid (EPA) treatment in patients with acute coronary syndrome (ACS) reduces adverse cardiovascular events.
Methods
This prospective, open-label, blind end point-randomized trial consisted of 241 patients with ACS. Patients were randomly assigned to receive pitavastatin (2mg/day) with or without 1800mg/day of EPA initiated within 24h after PCI. The primary endpoint was defined as cardiovascular events occurring within 1year, including death from a cardiovascular cause, nonfatal stroke, nonfatal MI and revascularization.
Results
The mean EPA/arachidonic acid ratio at follow-up was 0.40 in the control group and 1.15 in the EPA group. A primary endpoint event occurred in 11 patients (9.2%) in the EPA group and 24 patients (20.2%) in the control group (absolute risk reduction, 11.0%; hazard ratio, 0.42; 95% confidence interval, 0.21 to 0.87; P=0.02). Notably, death from a cardiovascular cause at 1year was significantly lower in the EPA group than in the control group (0.8% vs. 4.2%, P=0.04).
Conclusions
Early initiation of treatment with EPA combined with statin after successful primary PCI reduced cardiovascular events after ACS.
Clinical trial registration
UMIN Clinical Trials Registry (UMIN-CTR); Registry Number, UMIN000016723; URL, http://www.umin.ac.jp/ctr/index-j.htm.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.